109 related articles for article (PubMed ID: 11926699)
21. Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks.
Hankey GJ; Eikelboom JW
Neurology; 2005 Apr; 64(7):1117-21. PubMed ID: 15824331
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic interventions for prevention of recurrent ischemic stroke.
Kirshner HS
Am J Manag Care; 2008 Jun; 14(6 Suppl 2):S212-26. PubMed ID: 18611103
[TBL] [Abstract][Full Text] [Related]
23. Medical prevention of stroke and stroke recurrence in patients with TIA and minor stroke.
Weber R; Weimar C; Diener HC
Expert Opin Pharmacother; 2009 Aug; 10(12):1883-94. PubMed ID: 19558342
[TBL] [Abstract][Full Text] [Related]
24. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Biller J
J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
[TBL] [Abstract][Full Text] [Related]
25. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis.
Berger JS; Brown DL; Becker RC
Am J Med; 2008 Jan; 121(1):43-9. PubMed ID: 18187072
[TBL] [Abstract][Full Text] [Related]
26. [The combination of acetylsalicylic acid and dipyridamole is more effective in secondary prevention following transient ischaemic attack or cerebral infarction: the debate is closed].
Schrama E; Eusman JP
Ned Tijdschr Geneeskd; 2006 Dec; 150(48):2672; author reply 2672-3. PubMed ID: 17205946
[No Abstract] [Full Text] [Related]
27. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
[TBL] [Abstract][Full Text] [Related]
28. [The combination of acetylsalicylic acid and dipyridamole is more effective in secondary prevention following transient ischaemic attack or cerebral infarction: the debate is closed].
Offerhaus L
Ned Tijdschr Geneeskd; 2006 Dec; 150(48):2673; author reply 2673-4. PubMed ID: 17205947
[No Abstract] [Full Text] [Related]
29. The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population.
Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Fox K; Hennerici M; Mattle HP; Rothwell PM;
Cerebrovasc Dis; 2009; 27(6):608-13. PubMed ID: 19407444
[TBL] [Abstract][Full Text] [Related]
30. Rationale and design of the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study.
Hennerici MG;
Cerebrovasc Dis; 2009; 27 Suppl 3():28-32. PubMed ID: 19439938
[TBL] [Abstract][Full Text] [Related]
31. Statintherapy in the primary and the secondary prevention of ischaemic cerebrovascular diseases.
Feher A; Pusch G; Koltai K; Tibold A; Gasztonyi B; Szapary L; Feher G
Int J Cardiol; 2011 Apr; 148(2):131-8. PubMed ID: 20843571
[TBL] [Abstract][Full Text] [Related]
32. Dipyridamole with aspirin for secondary stroke prevention.
Norrving B
Lancet; 2006 May; 367(9523):1638-9. PubMed ID: 16714170
[No Abstract] [Full Text] [Related]
33. Evaluation of oral dipyridamole electrocardiography test in ischaemic heart disease.
Gupta PR; Avashty P; Garg AK; Prasad PV
J Assoc Physicians India; 1997 Nov; 45(11):860-2. PubMed ID: 11229186
[TBL] [Abstract][Full Text] [Related]
34. The drug trials that have influenced our clinical practice in acute ischaemic stroke.
Warlow C; Wardlaw J
Thromb Haemost; 1997 Jul; 78(1):558-61. PubMed ID: 9198215
[TBL] [Abstract][Full Text] [Related]
35. Transient ischemic attacks after dipyridamole-aspirin therapy.
Siegel AM; Sandor P; Kollias SS; Baumgartner RW
J Neurol; 2000 Oct; 247(10):807-8. PubMed ID: 11127540
[No Abstract] [Full Text] [Related]
36. “ Cerebrovascular stressing”: dipyridamole-induced S100B elevation predicts ischemic cerebrovascular events.
Molnar T; Szabo Z; Bartha E; Illes Z
Clin Chem Lab Med; 2013 Apr; 51(4):e69-72. PubMed ID: 23045382
[No Abstract] [Full Text] [Related]
37. [How important is dipyridamole in patients with ischemic heart disease?].
Spácil J
Cas Lek Cesk; 1990 May; 129(18):570-1. PubMed ID: 2350778
[TBL] [Abstract][Full Text] [Related]
38. [The combination of acetylsalicylic acid and dipyridamole is more effective in secondary prevention following transient ischaemic attack or cerebral infarction: the debate is closed].
Luijckx GJ; De Keyser JH
Ned Tijdschr Geneeskd; 2006 Aug; 150(33):1812-4. PubMed ID: 16967590
[TBL] [Abstract][Full Text] [Related]
39. [Dipyridamole test in the early detection of cerebrovascular disorders?].
Molnár T; Zámbó K; Schmidt E; Tekeres M
Orv Hetil; 2000 Dec; 141(50):2717-22. PubMed ID: 11189678
[TBL] [Abstract][Full Text] [Related]
40. Evidence for intravenous dipyridamole (persantin) producing a "coronary steal" effect in the ischaemic myocardium.
Wilcken DE; Paoloni HJ; Eikens E
Aust N Z J Med; 1971 Feb; 1(1):8-14. PubMed ID: 4934742
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
